Friday - May 16, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
C4 Therapeutics

Mettler-Toledo to Host First Quarter 2025 Earnings Conference Call

April 03, 2025 | Last Trade: US$1,143.36 25.55 2.29

COLUMBUS, Ohio / Apr 03, 2025 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its first quarter 2025 financial results after the market close on Thursday, May 1, 2025. The Company will host a conference call the following morning at 8:30 a.m. Eastern Time to discuss the results. To listen to the live audio webcast of the call, visit Events and Presentations on the Investor section of the Company’s website, investor.mt.com.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Stock Quote

Last Trade: US$1,143.36
Daily Change: 25.55 2.29
Daily Volume: 284,356
Market Cap: US$24.120B

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page